Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ceftriaxone + sulbactam + edetate disodium
- Development stage
- Unknown
- Lead developer
- Venus Remedies
- Modality
- Small Molecules
- Administration
- Intramuscular, Intravenous
01
Overview
Ceftriaxone + sulbactam + edetate disodium (marketed under the brand name Elores) is a patented fixed-dose combination antibiotic adjuvant entity developed by Venus Remedies to combat multi-drug resistant (MDR) Gram-negative bacterial infections, particularly those producing extended-spectrum beta-lactamases (ESBLs) and metallo-beta-lactamases (MBLs). The combination consists of ceftriaxone, a third-generation cephalosporin that inhibits bacterial cell wall synthesis; sulbactam, a beta-lactamase inhibitor that protects ceftriaxone from enzymatic degradation; and edetate disodium (EDTA), a non-antibiotic adjuvant that acts as an antibiotic resistance breaker. EDTA chelates divalent metal ions such as zinc (essential for MBL activity) and calcium (essential for efflux pump function and biofilm stability), thereby restoring the susceptibility of resistant pathogens to ceftriaxone. It is approved in India and several other countries for the treatment of complicated urinary tract infections (cUTIs), lower respiratory tract infections, and other severe systemic infections.
- Brand names
- Cefbact ESEloresMonocef-ESBZubacef SD
- Other names
- Ceftriaxone + EDTA + sulbactamCeftriaxone + sulbactam + disodium EDTACeftriaxone + sulbactam + disodium edetateCeftriaxone/disodium-edetate/sulbactamCeftriaxone/sulbactam/edetic acid
02
Targets
MG (Mycoplasma gallisepticum)PBP (Penicillin-binding protein family)Neuraminidaseβ-lactamase
Beyond the preview
Go deeper on ceftriaxone + sulbactam + edetate disodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ceftriaxone + sulbactam + edetate disodium.